On December 13, 2022, the Editorial Office was honored to have a special interview with Dr. Justin M. Balko from the Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Dr. Justin M. Balko published the article "MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression" in Cancer Drug Resistance in 2020, which attracted the attention of many researchers in this field. Based on this, the Editorial Office invited Dr. Balko to share more insights and the latest advances in breast cancer and drug resistance.
In the interview, Dr. Balko expressed his interest in clinical and translational research motivated him to pursue the field. Furthermore, he elaborated on why his lab has been studying MHC-I expression, especially the heterogeneity in MHC-I expression, and the results that we can expect in 2023.
In addition, he shared his views on the prospect in the field of breast cancer and his team's recent research progress. He mentioned that clinical trials on antibody-drug conjugates, the mechanisms of immune-related toxicity, the effect of MHZ-I on immunotherapy response, etc. are the exciting research of his lab. At the end of the interview, he encouraged those just starting their scientific careers in breast cancer to persevere and focus on the latest developments in the field and the updated data from clinical trials.
Introduction of Dr. Justin M. Balko
Dr. Justin M. Balko is an Associate Professor of Medicine, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center, Nashville, TN, USA. He and his team focus on improving treatment outcomes in breast cancer (particularly triple-negative breast cancer) as well as other solid tumors. He has authored and co-authored over 300 publications with 15,462 citations.
Respectfully Submitted by the Journal Editorial Office
Cancer Drug Resistance